Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis

Sirolimus (rapamycin) has been sparsely reported in the treatment of pediatric ulcerative colitis (PUC). Mucosal healing has not been examined in responders to the drug. We describe a case of infliximab refractory PUC where rapamycin induced sustained clinical remission along with mucosal healing. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellermayer, Richard, Chang, Andrew, Patel, Kalyani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158451/
https://www.ncbi.nlm.nih.gov/pubmed/37168909
http://dx.doi.org/10.1097/PG9.0000000000000183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158451/
https://www.ncbi.nlm.nih.gov/pubmed/37168909
http://dx.doi.org/10.1097/PG9.0000000000000183

Ejemplares similares